Yanhong Deng
DownloadHi-Res Photo
Cards
Titles
Senior Biostatistician; Co-Director of Analytics, Yale Center for Analytical Sciences
Contact Info
About
Titles
Statistician 3
Senior Biostatistician; Co-Director of Analytics, Yale Center for Analytical SciencesResearch
Research at a Glance
Yale Co-Authors
Frequent collaborators of Yanhong Deng's published research.
Publications Timeline
A big-picture view of Yanhong Deng's research output by year.
Geliang Gan, MPH, PhD
Michael Joyce
Brittany Craiglow, MD
Denis Sukhodolsky, PhD
Fred Sanford Gorelick, MD
Gary Désir, MD
7Publications
491Citations
Publications
2024
Psychosocial Evaluation of Living Kidney Donors: A Survey of Current Practices in the United States.
Clifton E, Winder G, Lentine K, Zimbrean P, Yadav A, Rubman S, Kalil R, Kumar V, Prashar R, Gan G, Deng Y, Joyce M, Holmes R, Laflen J, Bakhai D, Liapakis A, Doshi M. Psychosocial Evaluation of Living Kidney Donors: A Survey of Current Practices in the United States. Transplantation 2024 PMID: 38867351, DOI: 10.1097/tp.0000000000005095.Peer-Reviewed Original ResearchCitationsConceptsSubstance use disordersUse disorderActive anxiety disorderMental healthPosttraumatic stress disorderPsychosocial teamAnxiety disordersStress disorderActive suicidalitySelf-harmActivity depressionDisordersPsychosocial assessmentDepressionPsychosocial evaluationPost-donationUnited StatesClinical toolPsychosisLiving kidney donorsCannabisAnxietySuicideAbsolute contraindicationBest practicesIMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Wakelee H, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen Y, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava M, Bennett E, Gitlitz B, Felip E. IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2024, 42: lba8035-lba8035. DOI: 10.1200/jco.2024.42.17_suppl.lba8035.Peer-Reviewed Original ResearchAltmetricConceptsNon-small cell lung cancerDisease-free survivalResected non-small cell lung cancerPD-L1Overall survivalPhase III studyITT populationResected stage IB-IIIA non-small cell lung cancerStage IB-IIIA non-small cell lung cancerStage II-IIIA non-small cell lung cancerFollow-upDisease-free survival improvementDisease-free survival benefitPD-L1 TCStage II-IIIACell lung cancerIntent-to-treatAdjuvant atezolizumabOS trendIII studiesOS endpointSecondary endpointsAtezoSafety profileLung cancerIn‐person validation of the Ichthyosis Scoring System
Echeandia‐Francis C, Sun Q, Asch S, Bayart C, Benjamin L, Cipriano S, Craiglow B, Dyer J, Levy M, Lilly E, Newell B, Liang J, Gan G, Deng Y, Paller A, Choate K. In‐person validation of the Ichthyosis Scoring System. Pediatric Dermatology 2024, 41: 247-252. PMID: 38234066, DOI: 10.1111/pde.15508.Peer-Reviewed Original ResearchAltmetricConceptsInterrater intraclass correlation coefficientsIntrarater reliabilityIn-personIntraclass correlation coefficientIn-person evaluationContent validityInterrater reliabilityHeterogeneous group of skin disordersGroup of skin disordersIntraraterMedical professionalsInterrater agreementErythema evaluationIchthyosis subtypesPhotographic evaluationErythema scoreInterraterErythemaQuantify severitySkin disordersClinical utilityIchthyosisScoring systemHeterogeneous groupCorrelation coefficientFeasibility of an Interprofessional Inpatient Educational Intervention for Patients With Decompensated Cirrhosis
Haque L, McDonough M, Deng Y, Ciarleglio M, Liapakis A, Jakab S. Feasibility of an Interprofessional Inpatient Educational Intervention for Patients With Decompensated Cirrhosis. Gastro Hep Advances 2024, 3: 615-617. DOI: 10.1016/j.gastha.2024.03.011.Peer-Reviewed Original ResearchConcepts
2023
Clinical predictive value of renalase in post-ERCP pancreatitis
Muniraj T, Desir G, Gorelick F, Guo X, Ciarleglio M, Deng Y, Jamidar P, Farrell J, Aslanian H, Laine L. Clinical predictive value of renalase in post-ERCP pancreatitis. Gastrointestinal Endoscopy 2023, 99: 822-825.e1. PMID: 38103747, DOI: 10.1016/j.gie.2023.12.020.Peer-Reviewed Original ResearchAltmetricConceptsPost-ERCP pancreatitisRenalase levelsPlasma renalase levelsProspective cohort studyPotential clinical roleAcute experimental pancreatitisLongitudinal regression modelsPEP patientsPlasma renalaseCohort studyTertiary hospitalClinical roleExperimental pancreatitisRenalaseAbstractTextERCPPancreatitisFurther studiesAIMSRegression models
2016
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. British Journal Of Cancer 2016, 114: 737-743. PMID: 27022826, PMCID: PMC4984865, DOI: 10.1038/bjc.2016.45.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinFemaleFluorouracilFollow-Up StudiesHumansIrinotecanLeucovorinLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrganoplatinum CompoundsOxaliplatinPancreatic NeoplasmsPeritoneal NeoplasmsPrognosisProspective StudiesSurvival RateConceptsProgression-free survivalAdvanced pancreatic cancerPhase II studyOverall survivalAdverse eventsPancreatic cancerII studyResponse rateMedian progression-free survivalMulticentre phase II studyFluorodeoxyglucose positron emission tomographyUse of FOLFIRINOXMedian overall survivalHistorical control patientsMetastatic pancreatic cancerFirst prospective studyPositron emission tomographyControl patientsMetastatic diseaseProspective studyProspective dataFOLFIRINOXLAPCEmission tomographyPatients
2015
Effect of Parent Training vs Parent Education on Behavioral Problems in Children With Autism Spectrum Disorder: A Randomized Clinical Trial
Bearss K, Johnson C, Smith T, Lecavalier L, Swiezy N, Aman M, McAdam DB, Butter E, Stillitano C, Minshawi N, Sukhodolsky DG, Mruzek DW, Turner K, Neal T, Hallett V, Mulick JA, Green B, Handen B, Deng Y, Dziura J, Scahill L. Effect of Parent Training vs Parent Education on Behavioral Problems in Children With Autism Spectrum Disorder: A Randomized Clinical Trial. JAMA 2015, 313: 1524-1533. PMID: 25898050, PMCID: PMC9078140, DOI: 10.1001/jama.2015.3150.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAberrant Behavior Checklist-Irritability subscaleClinical Global Impressions-Improvement scaleParent trainingCo-primary outcomesAutism spectrum disorderClinical Global ImpressionSpectrum disorderDisruptive behaviorParent-reported outcomesParent educationPositive responseClinical improvementSecondary outcomesWeek 24Global ImpressionBlinded cliniciansClinical trialsClinical significanceMAIN OUTCOMEImprovement ScaleGreater severityTreatment assignment
Links & Media
News
- May 29, 2024
Renalase May Predict Post-ERCP Pancreatitis
- January 11, 2023
Discoveries & Impact (January 2023)
- March 17, 2022
Discoveries & Impact (March 2022)
- August 11, 2021
Discoveries & Impact (August 2021)
Get In Touch
Contacts
Locations
300 George Street
Academic Office
Ste Suite 555
New Haven, CT 06511